Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Toluene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.73 |
| ▸ | ACHE | P22303 | 1/20 | 0.73 |
| ▸ | CES2 | O00748 | 3/20 | 0.59 |
| ▸ | CES1 | P23141 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL27369787 | 1.00 | LMNA (0.73) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL2914390 | 1.00 | LMNA (0.73) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL7355317 | 1.00 | LMNA (0.73) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL7096668 | 0.97 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL7092275 | 0.97 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL3032586 | 0.97 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL5082155 | 0.97 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL28193175 | 0.97 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL28238801 | 0.97 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL27700453 | 0.97 | LMNA (0.69) | LMNATSHRALOX12ACHECES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 826 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234234-B2 | Method for synthesizing 1,7-naphthyridine derivatives | CHENGDA PHARMACEUTICALS CO., LTD. (CN) | 2025-02-25 | — | — | US | claimed |
| CN-116375706-B | Abamectin sodium key intermediate and preparation method thereof | 时森海(杭州)医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-3835302-B1 | DIISOCYANATE COMPOUND HAVING ANHYDROSUGAR ALCOHOL CORE AND PREPARATION METHOD THEREFOR | SAMYANG CORP (KR) | 2024-10-02 | — | — | EP | claimed |
| US-12060364-B2 | Diisocyanate compound having anhydrosugar alcohol core and preparation method therefor | SAMYANG CORPORATION (KR) | 2024-08-13 | — | — | US | claimed |
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| CN-117865889-A | Synthesis method of benzisoquinoline compound | 山东省药学科学院 | 2024-04-12 | — | — | CN | claimed |
| WO-2024024935-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE HAVING ANTINEOPLASTIC EFFECT | 第一三共株式会社 | 2024-02-01 | — | — | WO | claimed |
| EP-4286393-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2023-12-06 | — | — | EP | claimed |
| CN-116867795-A | Novel method for producing antibody-immunostimulant conjugate | 第一三共株式会社 | 2023-10-10 | — | — | CN | claimed |
| EP-3626721-B1 | SYNTHESIS OF ESTER AND AMIDE DERIVATIVES OF BETA-LACTAM NUCLEI | BONOMI PAOLO (FR) | 2023-09-06 | — | — | EP | claimed |
| EP-0951085-B1 | Dicarbonate additives for non-aqueous electrolyte in alkali metal electrochemical cells | GREATBATCH W LTD (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020136949-A1 | Electrochemical cell having an electrode with a dicarbonate additive in the electrode active mixture | GREATBATCH, INC. | 2002-09-26 | — | — | US | claimed |
| EP-1244159-A1 | Electrochemical cell having an electrode with a dicarbonate additive in the electrode active mixture | WILSON GREATBATCH LTD. (US) | 2002-09-25 | — | — | EP | claimed |
| US-6388134-B1 | CHEMICAL INTERMEDIATES | INKE, S.A. (ES) | 2002-05-14 | — | — | US | claimed |
| US-20020042522-A1 | Process for the preparation of derivative of 4-amino-3-hydroxypyrrole-2-carboxylic acid | PHARMACIA CORPORATION | 2002-04-11 | — | — | US | claimed |
| EP-1132373-A2 | NEW DERIVATIVES OF 6-(4-PHENYLBUTOXY)HEXYLAMINE AND PROCESS FOR PRODUCING SALMETEROL | VITA-INVEST, S.A. (ES) | 2001-09-12 | — | — | EP | claimed |
| US-6174629-B1 | ADDITION OF AT LEAST ONE DICARBONATE ADDITIVE TO AN ELECTROLYTE COMPRISING AN ALKALI METAL SALT DISSOLVED IN A SOLVENT MIXTURE THAT INCLUDES ETHYLENE CARBONATE, DIMETHYL CARBONATE, ETHYL METHYL CARBONATE AND DIETHYL CARBONATE | WILSON GREATBATCH LTD. | 2001-01-16 | — | — | US | claimed |
| EP-1005098-A2 | Alkali metal electrochemical cell having an improved cathode activated with a nonaqueous electrolyte having a passivation inhibitor additive | WILSON GREATBATCH LTD. (US) | 2000-05-31 | — | — | EP | claimed |
| US-6063526-A | AN ALKALI METAL, SOLID CATHODE, NONAQUEOUS ELECTROCHEMICAL CELL CAPABLE OF DELIVERING HIGH CURRENT PULSES, RAPIDLY RECOVERING ITS OPEN CIRCUIT VOLTAGE AND HAVING HIGH CURRENT CAPACITY; USE IN MEDICAL DEVICES SUCH AS DEFIBRILLATORS | WILSON GREATBATCH LTD. (US) | 2000-05-16 | — | — | US | claimed |
| EP-0951085-A1 | Dicarbonate additives for non-aqueous electrolyte in alkali metal electrochemical cells | WILSON GREATBATCH LTD. (US) | 1999-10-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | PAICS, COASY, CDS2 | LMNA 4487/4885TSHR 2895/4885ALOX12 2129/4885 |
| US-12234234-B2 | Method for synthesizing 1,7-naphthyridine derivatives | ALDH7A1, AKR7A2, APEH | LMNA 327/4885TSHR 2397/4885ALOX12 1426/4885 |
| US-12060364-B2 | Diisocyanate compound having anhydrosugar alcohol core and preparation method therefor | ADH1C, DAD1, UGT8 | LMNA 2717/4885TSHR 2600/4885ALOX12 1173/4885 |
| US-20020042522-A1 | Process for the preparation of derivative of 4-amino-3-hydroxypyrrole-2-carboxylic acid | LIG4, POLL, HPD | LMNA 1469/4885TSHR 4108/4885ALOX12 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.